Global Rank
#17079
Country Rank
n/a
Market Cap
312.23 M
Price
1.11
Change (%)
1.01%
Volume
812,664
Cereno Scientific AB (publ)'s latest marketcap:
312.23 M
As of 06/07/2025, Cereno Scientific AB (publ)'s market capitalization has reached $312.23 M. According to our data, Cereno Scientific AB (publ) is the 17079th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 312.23 M |
| Revenue (ttm) | 7.81 M |
| Net Income (ttm) | -11,258,830.01 |
| Shares Out | 281.7 M |
| EPS (ttm) | -0.04 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 05/22/2025 |
Market Cap Chart
Data Updated: 06/07/2025
Cereno Scientific AB (publ)'s yearly market capitalization.
Cereno Scientific AB (publ) has seen its market value grow from kr81.85 M to kr3.03 B since 2020, representing a total increase of 3,596.53% and an annual compound growth rate (CAGR) of 125.61%.
| Date | Market Cap | Change (%) |
|---|---|---|
| 06/07/2025 | kr3.03 B | 95.27% |
| 12/30/2024 | kr1.55 B | 44.86% |
| 12/29/2023 | kr1.07 B | 244.9% |
| 12/30/2022 | kr310.1 M | -42.01% |
| 12/30/2021 | kr534.73 M | 553.33% |
| 12/30/2020 | kr81.85 M |
Company Profile
About Cereno Scientific AB (publ)
Cereno Scientific AB (publ) is a clinical-stage biotechnology company focused on developing innovative therapeutics for cardiovascular and rare diseases. Headquartered in Gothenburg, Sweden, the company was founded in 2012 and operates globally.
Key Drug Candidates
- CS1 - A lead drug candidate currently in Phase II clinical trials for treating pulmonary arterial hypertension (PAH). CS1 functions as a histone deacetylase (HDAC) inhibitor with multiple therapeutic properties, including pressure reduction, anti-inflammatory effects, and anti-fibrotic benefits.
- CS585 & CS014 - Preclinical drug candidates targeting cardiovascular diseases, developed in collaboration with the University of Michigan.
Strategic Collaborations
- Partnership with the University of Michigan for preclinical development of CS585 and CS014.
- Collaboration with Abbott for the utilization of the CardioMEMS HF System.
- Alliance with the Pulmonary and Vascular Research Institute (PVRI) to advance research in cardiovascular and pulmonary diseases.
Frequently Asked Questions
-
What is Cereno Scientific AB (publ)'s (STO-CRNO.B) current market cap?As of 06/07/2025, Cereno Scientific AB (publ) (including the parent company, if applicable) has an estimated market capitalization of $312.23 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Cereno Scientific AB (publ) (STO-CRNO.B) rank globally by market cap?Cereno Scientific AB (publ) global market capitalization ranking is approximately 17079 as of 06/07/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.